Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Θ. Ψαλτοπούλου, Αν. Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ν. Γαβριατοπούλου, Επ. Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Θ. Σεργεντάνης, Ακαδημαϊκός Υπότροφος, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Έκφραση ιντεγκρινών και συσχέτιση με κλινικοπαθολογικά χαρακτηριστικά του καρκίνου του προστάτη: συστηματική ανασκόπηση βιβλιογραφίας και μετα-ανάλυση
Translated title:
Integrin expression and correlation with clinicopathological characteristics of prostate cancer: a systematic review and meta-analysis
Summary:
Background: The prompt identification of patients with poor prognosis is essential in order to improve the treatment outcomes in prostate cancer (PCa); as a novel approach, several molecular markers, including integrins, have been discussed as prognostic biomarkers. Our aim was to comprehensively examine aberrant expression of integrins in correlation with clinicopathological features and prognosis in prostate cancer by synthesizing all available evidence, in a systematic review and meta-analysis.
Methods: A systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. Scientific literature databases (Pubmed, Embase, and Scopus) were systematically searched until May 10, 2020. Random-effects (DerSimonian-Laird) models were used to estimate pooled odds ratios (ORs) for cross-sectional correlations with clinicopathological characteristics and relative risks (RRs) for longitudinal associations with prognosis.
Results: Fourteen studies were included with a total number of 3194 PCa cases examined (13 cross-sectional and four longitudinal cohort study arms). Correlation of low expression of α6 (pooled OR=0.10, 95% confidence interval, CI: 0.04-0.28, p<0.001) and β1 (pooled OR=0.45; 95% CI: 0.21-1.00, p=0.049) integrin with high Gleason score was noted. A borderline trend between reduced expression of α6 integrin and an advanced clinical stage of PCa (pooled OR=0.48; 95% CI: 0.22-1.03, p=0.06) was observed. No associations with biochemical recurrence and survival were documented.
Conclusions: Evidence on the association of low expression of integrins α6 and β1 and more advanced prostate cancer exists, whereas significant results on survival were not documented; further studies are warranted
Main subject category:
Health Sciences
Keywords:
Integrins, Clinicopathological characteristics, Prostate cancer, Gleason score, Cancer staging
Number of index pages:
02
